CRC Liver Metastases Cohort: Phase II of RO7198457 in Patients With ctDNA-positive, Resected Stage IV Colorectal Cancer Liver Metastases

This study is designed for patients who have recently undergone resection of their CRC liver metastases and identified ctDNA+ with a Roche Molecular ctDNA assay.

 

Key Eligibility Criteria

  • Patients must have CRC that has been surgically totally resected (R0 confirmed by pathology report) for primary tumors and liver metastases.
  • Patients must have detectable ctDNA.  ctDNA assay must be performed through this study or study BNT000-001 ctDNA screening protocol.

Treatment Regimens

Upon completion of standard adjuvant therapy, patients receive RO7198457.  This is an open label study without randomization.

RO7198457 administered as an IV infusion at protocol-specified intervals over 12 months

See ClinicalTrials.gov for more details:

Study Record

Sign up to be notified of new trials and Updates in the field: